相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Coronavirus Disease 2019 (COVID-19) Re-infection by a Phylogenetically Distinct Severe Acute Respiratory Syndrome Coronavirus 2 Strain Confirmed by Whole Genome Sequencing
Kelvin Kai-Wang To et al.
CLINICAL INFECTIOUS DISEASES (2021)
Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
Manli Wang et al.
CELL RESEARCH (2020)
SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
Markus Hoffmann et al.
CELL (2020)
Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion
Shuai Xia et al.
CELL RESEARCH (2020)
Surgical Mask Partition Reduces the Risk of Noncontact Transmission in a Golden Syrian Hamster Model for Coronavirus Disease 2019 (COVID-19)
Jasper Fuk-Woo Chan et al.
CLINICAL INFECTIOUS DISEASES (2020)
Umifenovir treatment is not associated with improved outcomes in patients with coronavirus disease 2019: a retrospective study
N. Lian et al.
CLINICAL MICROBIOLOGY AND INFECTION (2020)
Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells
Shutoku Matsuyama et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Arbidol monotherapy is superior to lopinavir/ritonavir in treating COVID-19
Zhen Zhu et al.
JOURNAL OF INFECTION (2020)
Therapeutic use of chloroquine and hydroxychloroquine in COVID-19 and other viral infections: A narrative review
Anwar M. Hashem et al.
TRAVEL MEDICINE AND INFECTIOUS DISEASE (2020)
A SARS-CoV-2 protein interaction map reveals targets for drug repurposing
David E. Gordon et al.
NATURE (2020)
The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro
Xi Wang et al.
CELL DISCOVERY (2020)
SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes
Waradon Sungnak et al.
NATURE MEDICINE (2020)
Disappearance of antibodies to SARS-CoV-2 in a -COVID-19 patient after recovery
Anding Liu et al.
CLINICAL MICROBIOLOGY AND INFECTION (2020)
Variant analysis of SARS-CoV-2 genomes
Takahiko Koyama et al.
BULLETIN OF THE WORLD HEALTH ORGANIZATION (2020)
Longer Duration of SARS-CoV-2 Infection in a Case of Mild COVID-19 With Weak Production of the Specific IgM and IgG Antibodies
Xuemin Guo et al.
FRONTIERS IN IMMUNOLOGY (2020)
SARS-CoV-2 and the Use of Chloroquine as an Antiviral Treatment
Mathieu E. Rebeaud et al.
FRONTIERS IN MEDICINE (2020)
Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection A Randomized Clinical Trial
Mayla Gabriela Silva Borba et al.
JAMA NETWORK OPEN (2020)
Chloroquine does not inhibit infection of human lung cells with SARS-CoV-2
Markus Hoffmann et al.
NATURE (2020)
Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing
Laura Riva et al.
NATURE (2020)
Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates
Pauline Maisonnasse et al.
NATURE (2020)
A perspective on potential antibody-dependent enhancement of SARS-CoV-2
Ann M. Arvin et al.
NATURE (2020)
Clinical and immunological assessment of asymptomatic SARS-CoV-2 infections
Quan-Xin Long et al.
NATURE MEDICINE (2020)
Rapid Decay of Anti-SARS-CoV-2 Antibodies in Persons with Mild Covid-19
F. Javier Ibarrondo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
A broad-spectrum virus- and host-targeting peptide against respiratory viruses including influenza virus and SARS-CoV-2
Hanjun Zhao et al.
NATURE COMMUNICATIONS (2020)
Antibody-dependent enhancement and SARS-CoV-2 vaccines and therapies
Wen Shi Lee et al.
NATURE MICROBIOLOGY (2020)
Re-positive coronavirus disease 2019 PCR test: could it be a reinfection?
A. A. Osman et al.
NEW MICROBES AND NEW INFECTIONS (2020)
The role of furin cleavage site in SARS-CoV-2 spike protein-mediated membrane fusion in the presence or absence of trypsin
Shuai Xia et al.
SIGNAL TRANSDUCTION AND TARGETED THERAPY (2020)
Comparative tropism, replication kinetics, and cell damage profiling of SARS-CoV-2 and SARS-CoV with implications for clinical manifestations, transmissibility, and laboratory studies of COVID-19: an observational study
Hin Chu et al.
LANCET MICROBE (2020)
Discovering drugs to treat coronavirus disease 2019 (COVID-19)
Liying Dong et al.
DRUG DISCOVERIES AND THERAPEUTICS (2020)
Arbidol and Other Low-Molecular-Weight Drugs That Inhibit Lassa and Ebola Viruses
C. E. Hulseberg et al.
JOURNAL OF VIROLOGY (2019)
Dual-functional peptide with defective interfering genes effectively protects mice against avian and seasonal influenza
Hanjun Zhao et al.
NATURE COMMUNICATIONS (2018)
Structural basis of influenza virus fusion inhibition by the antiviral drug Arbidol
Rameshwar U. Kadam et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2017)
Novel residues in the PA protein of avian influenza H7N7 virus affect virulence in mammalian hosts
Hanjun Zhao et al.
VIROLOGY (2016)
A novel peptide with potent and broad-spectrum antiviral activities against multiple respiratory viruses
Hanjun Zhao et al.
SCIENTIFIC REPORTS (2016)
Structure, Function, and Evolution of Coronavirus Spike Proteins
Fang Li
ANNUAL REVIEW OF VIROLOGY, VOL 3 (2016)
Protease inhibitors targeting coronavirus and filovirus entry
Yanchen Zhou et al.
ANTIVIRAL RESEARCH (2015)
Lack of Protection Against Ebola Virus from Chloroquine in Mice and Hamsters
Darryl Falzarano et al.
EMERGING INFECTIOUS DISEASES (2015)
Pharmacokinetics, Metabolism, and Excretion of the Antiviral Drug Arbidol in Humans
Pan Deng et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2013)
Pharmacokinetics of single and multiple oral doses of arbidol in healthy Chinese volunteers
Yaxin Sun et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2013)
Recombinant mouse beta-defensin 2 inhibits infection by influenza A virus by blocking its entry
Tianxiang Gong et al.
ARCHIVES OF VIROLOGY (2010)
Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus
Bo-Jian Zheng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Chloroquine is effective against influenza A virus in vitro but not in vivo
David J. Vigerust et al.
INFLUENZA AND OTHER RESPIRATORY VIRUSES (2007)
Aged BALB/c mice as a model for increased severity of severe acute respiratory syndrome in elderly humans
A Roberts et al.
JOURNAL OF VIROLOGY (2005)
Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
Martin J. Vincent et al.
VIROLOGY JOURNAL (2005)
分享论文
